A

Amgen

Makes biotech medicines for serious illnesses

Thought Leader Liaison Senior Manager

Full-TimeUpdated on 10/23/2026
$175.8k - $237.9k
Expert
Bachelor's, Master's, Associate's
Los Angeles, CA, USA+1 moreMore locations: Phoenix, AZ, USA
In PersonTerritory includes Los Angeles, Phoenix, and Las Vegas; up to 80% travel, including overnight programs and weekend conferences.
Growth & MarketingProduct Marketing

About the job

Requirements
  • Doctorate degree and 2 years of marketing or sales experience, or a master's degree and 4 years of marketing or sales experience, or a bachelor's degree and 6 years of marketing or sales experience, or an associate's degree and 10 years of marketing or sales experience, or a high school diploma or GED and 12 years of marketing or sales experience.
  • Customer-facing pharmaceutical or biotech industry experience in field sales, product marketing, or medical or clinical work in the same or a related therapeutic area is required.
  • Experience in the rheumatology and/or gastroenterology therapeutic area is strongly preferred.
  • Clinical experience in rare diseases or specialty biologics is strongly preferred.
  • Thought leader or demonstrated key opinion leader leadership experience is a plus.
  • A proven track record of consistent achievement or exceeding expectations in assigned responsibilities, goals, objectives, and relevant metrics, especially involving cross-functional matrix teams.
  • Previous experience in multiple commercial functions is beneficial.
  • Demonstrated experience customizing and executing timely action plans across various initiatives.
  • Demonstrated leadership, strategic agility, and persuasive aptitude.
  • Ability to collaborate with and/or lead cross-functional teams.
  • Ability to present ideas effectively by consolidating and customizing information.
  • Strong organizational, analytic, and time-management planning skills.
  • Exceptional clinical and business acumen.
  • Willingness to travel up to 80% of the time, including conferences on weekends, overnight programs, and attendance at key internal meetings.
  • Must reside within the territory boundaries given the travel requirements.
Responsibilities
  • Build relationships with existing and new thought leaders for involvement in current and future commercial activities through significant customer-facing time.
  • Create local peer-to-peer strategies in coordination with national and regional strategic marketing and sales business plans.
  • Liaise with sales and marketing to ensure thought leader concerns and needs are addressed in a timely and thorough manner.
  • Collaborate closely with the advocacy team to develop relationships with key physician and patient organizations.
  • Create and execute short- and long-term key opinion leader engagement plans.
  • Capture, synthesize, and share key thought leader insights to help shape brand strategy and prepare for future life-cycle management and competitor entry into the marketplace.
  • Identify evidence gaps across product and disease education through appropriate thought leader discussions and podium observations.
  • Disseminate thought leader insights to marketing, sales, market access, and other stakeholders to drive new strategies and tactical approaches and incorporate market trends into overall planning.
  • Coordinate leadership interactions at assigned national, regional, and state society conferences.
  • Initiate and pursue opportunities to involve the company in meaningful programs with thought leaders and strengthen its strategic market position.
  • Assist with speaker events, including speaker selection, speaker training, and reviewing current speaker programs to ensure consistent messaging and compliant execution.
  • Collaborate with the marketing team on peer-to-peer programs, including speaker training, and contribute to ongoing refinement of the U.S. speaker bureau.
  • Contribute to content development by providing customer insight and perspective to increase program impact and relevance.
Desired Qualifications
  • Experience in the rheumatology and/or gastroenterology therapeutic area.
  • Clinical experience in rare diseases or specialty biologics.
  • Thought leader or demonstrated key opinion leader leadership experience.
  • A proven track record of consistent achievement or exceeding expectations in assigned responsibilities, goals, objectives, and relevant metrics, especially involving cross-functional matrix teams.
  • Previous experience in multiple commercial functions.
  • Demonstrated experience customizing and executing timely action plans across various initiatives.
  • Demonstrated leadership, strategic agility, and persuasive aptitude.
  • Ability to collaborate with and/or lead cross-functional teams.
  • Ability to present ideas effectively by consolidating and customizing information.
  • Strong organizational, analytic, and time-management planning skills.
  • Exceptional clinical and business acumen.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.